{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:00:07Z","timestamp":1791655207823,"version":"4.3.4"},"reference-count":75,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2016,8,27]],"date-time":"2016-08-27T00:00:00Z","timestamp":1472256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Diabetes mellitus is a chronic condition associated with the metabolic impairment of insulin actions, leading to the development of life-threatening complications. Although many kinds of oral antihyperglycemic agents with different therapeutic mechanisms have been marketed, their undesirable adverse effects, such as hypoglycemia, weight gain, and hepato-renal toxicity, have increased demand for the discovery of novel, safer antidiabetic drugs. Since the important roles of the sodium-glucose cotransporter 2 (SGLT2) for glucose homeostasis in the kidney were recently elucidated, pharmacological inhibition of SGLT2 has been considered a promising therapeutic target for the treatment of type 2 diabetes. Since the discovery of the first natural SGLT2 inhibitor, phlorizin, several synthetic glucoside analogs have been developed and introduced into the market. Furthermore, many efforts to find new active constituents with SGLT2 inhibition from natural products are still ongoing. This review introduces the history of research on the development of early-generation SGLT2 inhibitors, and recent progress on the discovery of novel candidates for SGLT2 inhibitor from several natural products that are widely used in traditional herbal medicine.<\/jats:p>","DOI":"10.3390\/molecules21091136","type":"journal-article","created":{"date-parts":[[2016,8,29]],"date-time":"2016-08-29T10:18:38Z","timestamp":1472465918000},"page":"1136","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":116,"title":["Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents"],"prefix":"10.3390","volume":"21","author":[{"given":"Chang-Ik","family":"Choi","sequence":"first","affiliation":[{"name":"College of Pharmacy, Dongguk University-Seoul, Goyang 10326, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2016,8,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2337\/diab.40.4.405","article-title":"Role of oxidative stress in development of complications in diabetes","volume":"40","author":"Baynes","year":"1991","journal-title":"Diabetes"},{"key":"ref_2","unstructured":"International Diabetes Federation (2015). IDF Diabetes Atlas, International Diabetes Federation. [7th ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1039\/c2np00074a","article-title":"Recent discovery of plant-derived anti-diabetic natural products","volume":"29","author":"Hung","year":"2012","journal-title":"Nat. Prod. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1152\/ajplegacy.1938.122.3.765","article-title":"The renal tubular reabsorption of glucose in the normal dog","volume":"122","author":"Shannon","year":"1938","journal-title":"Am. J. physiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1152\/ajplegacy.1973.224.3.552","article-title":"Reevaluation of renal tubular glucose transport inhibition by phlorizin analogs","volume":"224","author":"Vick","year":"1973","journal-title":"Am. J. Physiol."},{"key":"ref_6","first-page":"F406","article-title":"Heterogeneity of sodium-dependent d-glucose transport sites along the proximal tubule: Evidence from vesicle studies","volume":"242","author":"Turner","year":"1982","journal-title":"Am. J. Physiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/330379a0","article-title":"Expression cloning and cDNA sequencing of the Na+\/glucose co-transporter","volume":"330","author":"Hediger","year":"1987","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1172\/JCI116972","article-title":"The human kidney low affinity Na+\/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose","volume":"93","author":"Kanai","year":"1994","journal-title":"J. Clin. Investig."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1681\/ASN.2010030246","article-title":"SGLT2 mediates glucose reabsorption in the early proximal tubule","volume":"22","author":"Vallon","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2337\/db11-1029","article-title":"Na+-d-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion","volume":"61","author":"Gorboulev","year":"2012","journal-title":"Diabetes"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"F188","DOI":"10.1152\/ajprenal.00518.2013","article-title":"Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia","volume":"306","author":"Rieg","year":"2014","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1172\/JCI102424","article-title":"Effect of diabetes and insulin on the maximum capacity of the renal tubules to reabsorb glucose","volume":"30","author":"Farber","year":"1951","journal-title":"J. Clin. Investig."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00232-001-0036-y","article-title":"Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat","volume":"182","author":"Vestri","year":"2001","journal-title":"J. Membr. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","article-title":"The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus","volume":"66","author":"Vallon","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/dmrr.532","article-title":"Phlorizin: A review","volume":"21","author":"Ehrenkranz","year":"2005","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2337\/diaclin.28.1.5","article-title":"Apple trees to sodium glucose co-transporter inhibitors: A review of SGLT2 inhibition","volume":"28","author":"White","year":"2010","journal-title":"Clin. Diabetes"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1172\/JCI100559","article-title":"The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man","volume":"12","author":"Chasis","year":"1933","journal-title":"J. Clin. Investig."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1172\/JCI112981","article-title":"Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats","volume":"79","author":"Rossetti","year":"1987","journal-title":"J. Clin. Investig."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1681\/ASN.V351078","article-title":"Effects of hyperglycemia on glucose transporters of the muscle: Use of the renal glucose reabsorption inhibitor phlorizin to control glycemia","volume":"3","author":"Dimitrakoudis","year":"1992","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"14112","DOI":"10.1074\/jbc.274.20.14112","article-title":"Chronic hyperglycemia triggers loss of pancreatic \u03b2 cell differentiation in an animal model of diabetes","volume":"274","author":"Jonas","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"782","DOI":"10.4158\/EP.14.6.782","article-title":"Inhibition of renal glucose absorption: A novel strategy for achieving glucose control in type 2 diabetes mellitus","volume":"14","author":"DeFronzo","year":"2008","journal-title":"Endocr. Pract."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"E141","DOI":"10.1152\/ajpendo.00712.2009","article-title":"Glucose transporters in the 21st century","volume":"298","author":"Thorens","year":"2010","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13300-013-0042-y","article-title":"Sodium glucose co-transporter type 2 (SGLT2) inhibitors: Targeting the kidney to improve glycemic control in diabetes mellitus","volume":"4","author":"Bays","year":"2013","journal-title":"Diabetes Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.2337\/diabetes.48.9.1794","article-title":"T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes","volume":"48","author":"Oku","year":"1999","journal-title":"Diabetes"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/jpet.106.110296","article-title":"Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level","volume":"320","author":"Katsuno","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1124\/jpet.108.140210","article-title":"Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models","volume":"327","author":"Fujimori","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_29","first-page":"574","article-title":"Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats","volume":"58","author":"Bickel","year":"2008","journal-title":"Arzneimittelforschung"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.tet.2009.12.003","article-title":"Synthesis of isotopically labelled SGLT inhibitors and their metabolites","volume":"66","author":"Derdau","year":"2010","journal-title":"Tetrahedron"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ejphar.2009.03.007","article-title":"Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats","volume":"609","author":"Fujimori","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejphar.2009.07.001","article-title":"Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice","volume":"618","author":"Katsuno","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1177\/0091270009351879","article-title":"Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus","volume":"50","author":"Hussey","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/0091270009352185","article-title":"Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: A randomized double-blind study","volume":"50","author":"Hussey","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1463-1326.2011.01462.x","article-title":"Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients","volume":"14","author":"Dobbins","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.2337\/dc12-0508","article-title":"Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes","volume":"35","author":"Mudaliar","year":"2012","journal-title":"Diabetes Care"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Hussey, E.K., Kapur, A., O\u2019Connor-Semmes, R., Tao, W., Rafferty, B., Polli, J.W., James, C.D., and Dobbins, R.L. (2013). Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. BMC Pharmacol. Toxicol., 14.","DOI":"10.1186\/2050-6511-14-25"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Kapur, A., O\u2019Connor-Semmes, R., Hussey, E.K., Dobbins, R.L., Tao, W., Hompesch, M., Smith, G.A., Polli, J.W., James, C.D., and Mikoshiba, I. (2013). First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus. BMC Pharmacol. Toxicol., 14.","DOI":"10.1186\/2050-6511-14-26"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/dom.12391","article-title":"Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes","volume":"17","author":"Sykes","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/dom.12393","article-title":"Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes","volume":"17","author":"Sykes","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1124\/dmd.114.062828","article-title":"Pharmacokinetics and pharmacodynamics of the SGLT2 inhibitor remogliflozin etabonate in subjects with mild and moderate renal impairment","volume":"43","author":"Walker","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"9213","DOI":"10.1016\/S0040-4039(00)01709-3","article-title":"A method for preparing C-glycosides related to phlorizin","volume":"41","author":"Link","year":"2000","journal-title":"Tetrahedron Lett."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1021\/jm701272q","article-title":"Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes","volume":"51","author":"Meng","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2337\/db07-1472","article-title":"Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats","volume":"57","author":"Han","year":"2008","journal-title":"Diabetes"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.2008.250","article-title":"Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/dc08-1863","article-title":"Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes","volume":"32","author":"List","year":"2009","journal-title":"Diabetes Care"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.2337\/dc09-0517","article-title":"A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: Applicability of a novel insulin-independent treatment","volume":"32","author":"Wilding","year":"2009","journal-title":"Diabetes Care"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: A randomized, double-blind, placebo-controlled, phase III trial","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1463-1326.2011.01434.x","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: A randomized, 24-week, double-blind, placebo-controlled trial","volume":"13","author":"Strojek","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2337\/dc11-0606","article-title":"Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active controlled noninferiority trial","volume":"34","author":"Nauck","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2337\/dc11-1693","article-title":"Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.1021\/jm100332n","article-title":"Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus","volume":"53","author":"Nomura","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.2337\/dc11-1926","article-title":"Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1463-1326.2012.01558.x","article-title":"Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin","volume":"14","author":"Devineni","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dom.12054","article-title":"Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise","volume":"15","author":"Cefalu","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.12090","article-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease","volume":"15","author":"Yale","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","article-title":"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: Characterisation and comparison with other SGLT-2 inhibitors","volume":"14","author":"Grampler","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.2337\/dc15-0642","article-title":"Sodium-glucose cotransporter inhibitors: Effects on renal and intestinal glucose transport: From bench to bedside","volume":"38","author":"Mudaliar","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1016\/j.bmc.2007.03.011","article-title":"Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens","volume":"15","author":"Sato","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s00044-014-1200-0","article-title":"Sodium-glucose-linked transporter 2 inhibitors from Sophora flavescens","volume":"24","author":"Yang","year":"2015","journal-title":"Med. Chem. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.bmcl.2009.12.036","article-title":"Cyclic diarylheptanoids as Na+-glucose cotransporter (SGLT) inhibitors from Acer nikoense","volume":"20","author":"Morita","year":"2010","journal-title":"Bioorg. Med. Chem. Letter."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.bmc.2010.01.077","article-title":"Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter","volume":"18","author":"Arai","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1021\/np9007987","article-title":"Gneyulins A and B, stilbene trimers, and noidesols A and B, dihydroflavonol-C-glucosides, from the bark of Gnetum gnemonoides","volume":"73","author":"Shimokawa","year":"2010","journal-title":"J. Nat. Prod."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jep.2015.06.010","article-title":"Sophora flavescens Ait.: Traditional usage, phytochemistry and pharmacology of an important traditional Chinese medicine","volume":"172","author":"He","year":"2015","journal-title":"J. Ethnopharmacol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1248\/cpb.26.2805","article-title":"Studies on the constituents of Aceraceae plants. II. Structure of aceroside I, a glucose of a novel cyclic diarylheptanoids from Acer nikoense Maxim","volume":"26","author":"Nagai","year":"1978","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.fitote.2011.04.013","article-title":"Bisindole alkaloids and secoiridoids from Alstonia macrophylla Wall. ex G. Don","volume":"82","author":"Changwichit","year":"2011","journal-title":"Fitoterapia"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jep.2014.01.025","article-title":"Alstonia scholaris (L.) R. Br. and Alstonia macrophylla Wall. ex G. Don: A comparative review on traditional uses, phytochemistry and pharmacology","volume":"153","author":"Khyade","year":"2014","journal-title":"J. Ethnopharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.chroma.2005.01.025","article-title":"Preparative separation and purification of deoxyschisandrin and gamma-schisandrin from Schisandra chinensis (Turcz.) Baill by high-seed counter-current chromatography","volume":"1066","author":"Huang","year":"2005","journal-title":"J. Chromatogr. A"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/09637486.2011.627840","article-title":"Panax ginseng, Rhodiola rosea and Schisandra chinensis","volume":"63","author":"Chan","year":"2012","journal-title":"Int. J. Food Sci. Nutr."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ddr.21233","article-title":"Antidiabetic effect of Schisandrae Chinensis Fructus involves inhibition of the sodium glucose cotransporter","volume":"76","author":"Qu","year":"2015","journal-title":"Drug Dev. Res."},{"key":"ref_72","unstructured":"INVOKANA\u00ae (Canagliflozin) Prescribing Information, Available online: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/204042s015s019lbl.pdf."},{"key":"ref_73","unstructured":"JARDIANCE\u00ae (Empagliflozin) Prescribing Information, Available online: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/204629s005lbl.pdf."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"8770","DOI":"10.1021\/jm101080v","article-title":"Discovery of non-glycoside sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors by ligand-based virtual screening","volume":"53","author":"Wu","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5414\/CP202158","article-title":"Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants","volume":"53","author":"Devineni","year":"2015","journal-title":"Int. J. Clin. Pharmacol. Ther."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/21\/9\/1136\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:29:25Z","timestamp":1760210965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/21\/9\/1136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,27]]},"references-count":75,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2016,9]]}},"alternative-id":["molecules21091136"],"URL":"https:\/\/doi.org\/10.3390\/molecules21091136","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,27]]}}}